A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Schizophrenia
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: Triple (Participant, Care Provider, Investigator)Primary Purpose: Basic Science
Participation Requirements
- Age
- Between 18 years and 45 years
- Gender
- Both males and females
Description
Single administration, double-blinded, placebo-controlled (2 subjects in each group will take placebo,8 subjects in each group will take CY150112) and 6 dose groups (0.5mg, 1.5mg, 4.5mg, 10mg, 18mg and 24mg). This study comprises a screening period (between signing of the informed consent form and D...
Single administration, double-blinded, placebo-controlled (2 subjects in each group will take placebo,8 subjects in each group will take CY150112) and 6 dose groups (0.5mg, 1.5mg, 4.5mg, 10mg, 18mg and 24mg). This study comprises a screening period (between signing of the informed consent form and Day -1), baseline period (Day -1), treatment period (Days 1-5) and follow-up period(Days 12 or 7 days after discharge ).
Tracking Information
- NCT #
- NCT04839926
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Hua Fang li, MD Shanghai Mental Health Center
Get Well Soon